Spiral Therapeutics
Spiral Therapeutics is a clinical-stage biopharmaceutical company dedicated to developing innovative therapies for inner ear disorders, focusing on balance disorders and hearing loss. They leverage a proprietary drug delivery platform, MICS™, to enable precise, durable, and minimally invasive drug delivery directly to the cochlea. Their lead program, SPT-2101, is a sustained-release steroid formulation for the treatment of inner ear inflammation, with promising clinical trial results showing significant reduction in vertigo for patients with Meniere’s disease.
Industries
Nr. of Employees
small (1-50)
Spiral Therapeutics
Patents
Minimally-invasive tools and methods for accessing the middle and inner ear through the tympanic membrane
US-12164095-B2
View DetailsIntratympanic injector devices and needles for delivery of drugs and methods of use
US-12138436-B2
View Details
Minimally-invasive tools and methods for accessing the middle and inner ear through the tympanic membrane
US-12164095-B2
View DetailsIntratympanic injector devices and needles for delivery of drugs and methods of use
US-12138436-B2
View DetailsNews & Updates
Spiral announced the successful completion of a clinical trial of SPT-2101 in Meniere’s disease, showing significant reduction in vertigo frequency and severity. The trial involved 21 patients across Australia, with no serious adverse events reported. The treatment showed superior vertigo management compared to control, with a statistically significant difference.
Spiral announced the successful completion of a clinical trial of SPT-2101 in Meniere’s disease, showing significant reduction in vertigo frequency and severity. The trial involved 21 patients across Australia, with no serious adverse events reported. The treatment showed superior vertigo management compared to control, with a statistically significant difference.
Spiral Therapeutics received the Hearing Technology Innovator Award for its innovative Drug Delivery Platform, recognizing its contribution to the hearing industry.
Spiral announced the successful completion of a clinical trial of SPT-2101 in Meniere’s disease, showing significant reduction in vertigo frequency and severity. The trial involved 21 patients across Australia, with no serious adverse events reported. The treatment showed superior vertigo management compared to control, with a statistically significant difference.
Spiral announced the successful completion of a clinical trial of SPT-2101 in Meniere’s disease, showing significant reduction in vertigo frequency and severity. The trial involved 21 patients across Australia, with no serious adverse events reported. The treatment showed superior vertigo management compared to control, with a statistically significant difference.
Spiral Therapeutics received the Hearing Technology Innovator Award for its innovative Drug Delivery Platform, recognizing its contribution to the hearing industry.